{"title":"将 C 反应蛋白-白蛋白-淋巴细胞指数作为肾癌手术患者病情进展的新型生物标记物","authors":"Hiroshi Hirata, Nakanori Fujii, Shintaro Oka, Kimihiko Nakamura, Kosuke Shimizu, Keita Kobayashi, Toshiya Hiroyoshi, Naohito Isoyama, Koji Shiraishi","doi":"10.21873/cdp.10391","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Some patients with renal cell carcinoma (RCC) develop early or late recurrence after surgery. However, there is no clear consensus on which patients with postoperative RCC should be treated. This study aimed to establish a biomarker for selecting patients who are at a higher risk of relapse following renal cancer surgery.</p><p><strong>Patients and methods: </strong>A total of 378 patients who underwent nephrectomy or partial nephrectomy for a diagnosis of RCC at our hospital were included, with a focus on pT3 cases at high risk of recurrence. Factors associated with postoperative progression, including pathological and hematological parameters, were examined.</p><p><strong>Results: </strong>Sarcomatoid features, Fuhrman grade 4, and C-reactive protein-albumin-lymphocyte (CALLY) index were statistically significant predictive factors for progression-free survival after surgery (p<0.0011, p=0.0047, and p<0.0001, respectively). In the multivariate Cox proportional regression analysis, the CALLY index was the most statistically significant predictor of the risk of postoperative recurrence (p=0.0002).</p><p><strong>Conclusion: </strong>In addition to the existing risk factors for RCC recurrence, such as sarcomatoid features and Fuhrman grade, we propose that the CALLY index is a predictor of postoperative recurrence and that patients with a low CALLY index are good candidates for postoperative treatment. Our study may help select patients with pT3 disease with a high risk of recurrence who require postoperative treatment.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"748-753"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534045/pdf/","citationCount":"0","resultStr":"{\"title\":\"C-reactive Protein-albumin-lymphocyte Index as a Novel Biomarker for Progression in Patients Undergoing Surgery for Renal Cancer.\",\"authors\":\"Hiroshi Hirata, Nakanori Fujii, Shintaro Oka, Kimihiko Nakamura, Kosuke Shimizu, Keita Kobayashi, Toshiya Hiroyoshi, Naohito Isoyama, Koji Shiraishi\",\"doi\":\"10.21873/cdp.10391\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Some patients with renal cell carcinoma (RCC) develop early or late recurrence after surgery. However, there is no clear consensus on which patients with postoperative RCC should be treated. This study aimed to establish a biomarker for selecting patients who are at a higher risk of relapse following renal cancer surgery.</p><p><strong>Patients and methods: </strong>A total of 378 patients who underwent nephrectomy or partial nephrectomy for a diagnosis of RCC at our hospital were included, with a focus on pT3 cases at high risk of recurrence. Factors associated with postoperative progression, including pathological and hematological parameters, were examined.</p><p><strong>Results: </strong>Sarcomatoid features, Fuhrman grade 4, and C-reactive protein-albumin-lymphocyte (CALLY) index were statistically significant predictive factors for progression-free survival after surgery (p<0.0011, p=0.0047, and p<0.0001, respectively). In the multivariate Cox proportional regression analysis, the CALLY index was the most statistically significant predictor of the risk of postoperative recurrence (p=0.0002).</p><p><strong>Conclusion: </strong>In addition to the existing risk factors for RCC recurrence, such as sarcomatoid features and Fuhrman grade, we propose that the CALLY index is a predictor of postoperative recurrence and that patients with a low CALLY index are good candidates for postoperative treatment. Our study may help select patients with pT3 disease with a high risk of recurrence who require postoperative treatment.</p>\",\"PeriodicalId\":72510,\"journal\":{\"name\":\"Cancer diagnosis & prognosis\",\"volume\":\"4 6\",\"pages\":\"748-753\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534045/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer diagnosis & prognosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21873/cdp.10391\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer diagnosis & prognosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21873/cdp.10391","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景/目的:一些肾细胞癌(RCC)患者在术后会出现早期或晚期复发。然而,对于哪些术后 RCC 患者应该接受治疗,目前还没有明确的共识。本研究旨在建立一种生物标志物,用于选择肾癌术后复发风险较高的患者:共纳入了378名在我院因诊断为RCC而接受肾切除术或肾部分切除术的患者,重点关注复发风险较高的pT3病例。研究人员对与术后进展相关的因素(包括病理学和血液学参数)进行了分析:结果:肉瘤样特征、Fuhrman 4 级和 C 反应蛋白-白蛋白-淋巴细胞(CALLY)指数是术后无进展生存率的统计学显著预测因素(p 结论:除了现有的术后无进展生存率风险因素外,肉瘤样特征、Fuhrman 4 级和 C 反应蛋白-白蛋白-淋巴细胞(CALLY)指数也是术后无进展生存率的显著预测因素:除了肉瘤特征和Fuhrman分级等现有的RCC复发风险因素外,我们认为CALLY指数也是术后复发的预测因素,CALLY指数低的患者适合术后治疗。我们的研究可能有助于选择需要术后治疗的高复发风险 pT3 患者。
C-reactive Protein-albumin-lymphocyte Index as a Novel Biomarker for Progression in Patients Undergoing Surgery for Renal Cancer.
Background/aim: Some patients with renal cell carcinoma (RCC) develop early or late recurrence after surgery. However, there is no clear consensus on which patients with postoperative RCC should be treated. This study aimed to establish a biomarker for selecting patients who are at a higher risk of relapse following renal cancer surgery.
Patients and methods: A total of 378 patients who underwent nephrectomy or partial nephrectomy for a diagnosis of RCC at our hospital were included, with a focus on pT3 cases at high risk of recurrence. Factors associated with postoperative progression, including pathological and hematological parameters, were examined.
Results: Sarcomatoid features, Fuhrman grade 4, and C-reactive protein-albumin-lymphocyte (CALLY) index were statistically significant predictive factors for progression-free survival after surgery (p<0.0011, p=0.0047, and p<0.0001, respectively). In the multivariate Cox proportional regression analysis, the CALLY index was the most statistically significant predictor of the risk of postoperative recurrence (p=0.0002).
Conclusion: In addition to the existing risk factors for RCC recurrence, such as sarcomatoid features and Fuhrman grade, we propose that the CALLY index is a predictor of postoperative recurrence and that patients with a low CALLY index are good candidates for postoperative treatment. Our study may help select patients with pT3 disease with a high risk of recurrence who require postoperative treatment.